MediGait Announces Results from Cerebral Palsy Trial Demonstrating Benefits of Its GaitAid Device in Improving Walking

Share Article

First Ever Controlled Clinical Trial in Cerebral Palsy Patients with the GaitAid by MediGait

MediGait, LTD today announced results from its clinical trial with the GaitAid device for Cerebral Palsy patients. The findings, accepted for publication by Neuromodulation Journal, demonstrated that all children with Cerebral Palsy participating in the study had a residual improvement in walking after only 20 minutes using the GaitAid device.

Cerebral palsy affects an estimated 764,000 people in the United States, according to United Cerebral Palsy, with approximately 8,000 babies and 1,200 to 1,500 preschool-age children diagnosed with the condition each year. Caused by damage to one or more areas of the developing brain, cerebral palsy is characterized by an inability to control motor function fully, particularly muscle control and coordination.

The GaitAid from MediGait is an easy to use at-home virtual reality device. It includes a small unit that is clipped onto the patient’s pants and a pair of special goggles with headphones, which provide audio and visual stimulation in response to the patient’s movements. Simply walking with the device for 20 minutes a day was shown to improve walking for Parkinson’s disease, Multiple Sclerosis, Stroke and now Cerebral Palsy patients.

Ten children with Cerebral Palsy as well as ten healthy aged matched controls participated in the study. The children walked along a 10-meter path while wearing the GaitAid device for twenty minutes. After a twenty-minute break, the children walked the path without the device while walking parameters were measured testing for a residual improvement. All children with Cerebral Palsy gained a significant improvement while the control group showed no difference. The degree of improvement was found to be proportional to the rate of disability – i.e. the children with the most dysfunctional walking pattern gained the greatest benefit.

The paper describing the study is available online: http://www.medigait.com/neuromod.pdf

Dr. Brad Marcus of Medical Rehabilitation & Kinematics Lab in San Diego has already been using the GaitAid with his Cerebral Palsy patients for the last year and achieving great results while combining the GaitAid with other treatment modalities. The current study was aimed at measuring the effects of using the GaitAid alone in an out-of-clinic environment. The results suggest that these children can improve at home by using the GaitAid.

The GaitAid is available for a 30-day at-home trial period.

More information is available online: http://www.medigait.com
Email: support(at)medigait.com
Phone: 888-777-9906

About MediGait – MediGait LTD (http://www.MediGait.com) headquartered in Haifa, Israel was founded by Yoram Baram, a Professor of Computer Science and incumbent of the Roy Matas / Winnipeg Chair in Biomedical Engineering at the Technion, Israel Institute of Technology. MediGait creates breakthrough movement feedback devices to improve quality of life for movement disorder patients.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Audrey Holmes-Baram
MediGait
888-777-9906
Email >
Visit website